POINT ROBERTS, Wash. and DELTA, British Columbia, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Investorideas.com, a leading investor news resource covering
cannabis stocks releases a snapshot looking at the global expansion of the cannabis industry and the companies looking at new
international markets as regulations change.
As new international markets being to open, both cannabis giants as well as smaller cannabis technology companies are now making
the necessary preparations to enter this international space.
The Greater Cannabis Company, Inc. (OTC:GCAN), recently announced that it has entered into a letter of intent with iCAN Cannabis to
expand distribution of its eluting patch platform into key global markets. The eluting patch platform is an innovative delivery
system which uses a patented mucoadhesive and multilayered orally dissolving thin film to deliver a precise dose of cannabinoids
into the body through the buccal mucosa. Clinical studies, funded in part by the National Institutes of Health (NIH), have shown
the delivery system’s capability in achieving higher bioavailability and desired results in the body using lower and controlled
dosing when compared to other routes of administration.
The agreement with iCAN will include commercial ready formulations to meet medical and recreational market demands. Distribution
and marketing rights for iCAN will include Israel, Australia, South Africa, Netherlands, Mexico, Colombia, Panama, Germany,
Austria, Switzerland, Malta, Macedonia and Portuguese territories.
In their recent news release, Aitan Zacharin, CEO of Greater Cannabis said, “I am pleased to announce our
partnership with iCAN. Saul is an industry leader who is at the forefront of everything tech in cannabis. His desire to partner
with us is a testament to the strength of our technology and its capabilities. We are excited to establish this important
partnership in the medical and adult-use cannabis industry. We are focused on transactions that will accelerate commercialization
of our products and the iCAN deal does that globally. iCAN shares our enthusiasm for seeing healthier, standardized,
pharmaceutical-grade and more cost-effective cannabis products introduced into the market. We look forward to working with iCan to
bring our cutting-edge technology to consumers worldwide.”
Similarly, in December of 2018, Aphria Inc. (TSX:APHA.TO)
(NYSE:APHA)
and Rapid Dose Therapeutics Inc. announced that they have expanded the scope of their previously announced agreement where Aphria
has been granted exclusive preferred rights to license, manufacture, distribute and sell RDT's QuickStrip™ innovative, proprietary
delivery technology for the cannabis market to Germany.
In their news release, Jakob Ripshtein, President of Aphria commented that "Germany is one of the most
sought-after cannabis markets today and Aphria continues to take a comprehensive approach to ensure a leading presence in the
country as the opportunity evolves." Ripshtein continued, "Aphria is committed to bringing advanced products and innovations to
cannabis markets around the world, and this agreement with RDT will enable us to bring QuickStrip™ technology to the German market
and offer a unique nutraceutical product that delivers a consistent dosage."
Back in November, Canopy Growth Corp. (NYSE:CGC) (TSX:WEED.TO), one of
the world’s biggest medical cannabis companies announced they would spend more than 100 million euros (US$115 million) to expand
production in the EU over the next two years, according to Pierre Debs, managing director at Canopy’s Spectrum Cannabis Europe
division.
In one news article, Debs commented that Germany and the EU overall “are the most exciting federally
regulated medical cannabis markets outside of Canada.” Debs continued in the phone interview saying, “Things are going to grow not
too differently than what happened in Canada. We’re going to need significant production facilities.”
AgraFlora Organics International Inc. (CSE: AGRA) (OTCPK: PUFXF) has
also been looking at the international sector with their recent announcement that they have engaged good manufacturing practices
(GMP) facility experts to design post production exports for the European Union (EU) in preparation for the first crop of cannabis
to be planted at its large-scale Delta Greenhouse Complex later this year. The Company has also initiated discussions regarding
supply agreements and product development partnerships with several European Union based pharma companies.
In their recent release, Derek Ivany, President and CEO, AgraFlora Organics International Inc. said, "I
am very pleased to announce we have engaged European GMP facility experts to design post production products for export
markets."
As the world is watching the successes and struggles of the Canadian and US cannabis markets, there is an increasing need for
companies to take the proper steps and make the investments or face the possibility of being left out of the global cannabis
community.
For investors following cannabis stocks, Investor Ideas has created a stock directory of publicly traded CSE, TSX, TSXV, OTC,
NASDAQ, NYSE, ASX Marijuana/Hemp Stocks
About Investorideas.com - News that Inspires Big Investing Ideas
https://www.investorideas.com/About/
Follow us on Cannabis Social Media
https://www.facebook.com/Investorideaspotcasts/
https://twitter.com/MJInvestorIdeas
https://www.instagram.com/potcasts_investorideas/
This news is published on the Investorideas.com Newswire – News that Inspires big ideas Disclaimer/Disclosure: Investorideas.com
is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation
and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this news article featuring GCAN is a paid for
news creation service on Investorideas.com. Learn more about costs and our services https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all
OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell
cannabis products.
Contact Investorideas.com
800-665-0411
